Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alder BioPharmaceuticals licenses non-exclusive rights to Teva's eptinezumab

Executive Summary

As part of a patent litigation settlement, Teva Pharmaceutical Industries Ltd. licensed Alder BioPharmaceuticals Inc. non-exclusive worldwide rights (excluding Japan and Korea) to develop, manufacture, and commercialize its CGRP (calcitonin gene-related peptide antagonist antibodies) patent portfolio.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Reverse Licensing
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies